SGLT2 Inhibitors May Reduce Alzheimer’s Risk by 43 Percent

Recent clinical evidence suggests that SGLT2 inhibitors, a class of medications primarily used to manage type 2 diabetes, may significantly reduce the risk of developing Alzheimer’s disease. Longitudinal data indicate a risk reduction of approximately 43% in patients treated with these agents, shifting the medical understanding of neurodegeneration toward a cardiometabolic framework.

The Cardiometabolic Connection to Neurodegeneration

The traditional view of Alzheimer’s disease as an isolated neurological pathology is increasingly being challenged by metabolic research.

Mechanisms of Neuroprotection

The mechanism behind this risk reduction is multifaceted.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.